Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Weisel, Katja; Dimopoulos, Meletios; Moreau, Philippe; Yagci, Munci; Larocca, Alessandra; Kanate, Abraham S.; Vural, Filiz; Cascavilla, Nicola; Basu, Supratik; Johnson, Peter; Byeff, Peter; Hus, Marek; Rodriguez-Otero, Paula; Muelduer, Ercan; Anttila, Pekka; Hayden, Patrick J.; Krauth, Maria-Theresa; Lucio, Paulo; Ben-Yehuda, Dina; Mendeleeva, Larisa; Guo, Shien; Yu, Xin; Grote, Lara; Biyukov, Tsvetan; Dhanasiri, Sujith; Richardson, Paul

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Autor(en):

Weisel, Katja; Dimopoulos, Meletios; Moreau, Philippe; Yagci, Munci; Larocca, Alessandra; Kanate, Abraham S.; Vural, Filiz; Cascavilla, Nicola; Basu, Supratik; Johnson, Peter; Byeff, Peter; Hus, Marek; Rodriguez-Otero, Paula; Muelduer, Ercan; Anttila, Pekka; Hayden, Patrick J.; Krauth, Maria-Theresa; Lucio, Paulo; Ben-Yehuda, Dina; Mendeleeva, Larisa; Guo, Shien; Yu, Xin; Grote, Lara; Biyukov, Tsvetan; Dhanasiri, Sujith; Richardson, Paul

Tübinger Autor(en):

Weisel, Katja

Erschienen in:

Leukemia & Lymphoma (2020), Bd. 61, H. 8, S. 1850-1859

Verlagsangabe:

Taylor & Francis Ltd

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1080/10428194.2020.1747066

ISSN:

1029-2403